Technical Analysis for IKNA - Ikena Oncology, Inc.

Grade Last Price % Change Price Change
F 17.99 -2.49% -0.46
IKNA closed down 2.49 percent on Friday, April 16, 2021, on 13 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical IKNA trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Calm After Storm Range Contraction -2.49%
Narrow Range Bar Range Contraction -2.49%
Outside Day Range Expansion -2.49%
NR7 Range Contraction 1.75%
Hot IPO Pullback Bullish Swing Setup 0.56%
Older End-of-Day Signals for IKNA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown 1 day ago
Down 5% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Cancer Therapies Signal Transduction Novel Cancer Transcription Factors

Is IKNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 37.61
52 Week Low 14.16
Average Volume 436,671
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 19.04
Average True Range 5.33
ADX 0.0
+DI 10.83
-DI 12.37
Chandelier Exit (Long, 3 ATRs ) 21.63
Chandelier Exit (Short, 3 ATRs ) 30.14
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -1.20
MACD Signal Line -0.53
MACD Histogram -0.6707
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.84
Resistance 3 (R3) 19.77 19.10 19.53
Resistance 2 (R2) 19.10 18.63 19.13 19.42
Resistance 1 (R1) 18.54 18.34 18.21 18.61 19.32
Pivot Point 17.87 17.87 17.70 17.90 17.87
Support 1 (S1) 17.31 17.40 16.98 17.38 16.66
Support 2 (S2) 16.64 17.11 16.67 16.56
Support 3 (S3) 16.08 16.64 16.45
Support 4 (S4) 16.15